We are live on ! Find out more
MACK

Merrimack Pharmaceuticals, Inc.
MACK

Delisted

MACK was delisted on the 17th of May, 2024.

Back to rankings

139 hedge funds and large institutions have $636M invested in Merrimack Pharmaceuticals, Inc. in 2015 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 48 increasing their positions, 39 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 20

23% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 39

3% more funds holding

Funds holding: 135 → 139 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less capital invested

Capital invested by funds: $663M → $636M (-$26.7M)

25% less call options, than puts

Call options by funds: $539K | Put options by funds: $723K

Holders
139
Holders Change
+4
Holders Change %
+2.96%
% of All Funds
3.65%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
25
Increased
48
Reduced
39
Closed
20
Calls
$539K
Puts
$723K
Net Calls
-$184K
Net Calls Change
-$1.81M

Top Buyers

Rank Fund Capital Flow
1
PI
Putnam Investments
Massachusetts
+$12.9M
2
Millennium Management
Millennium Management
New York
+$12.7M
3
TA
Teachers Advisors
New York
+$8.41M
4
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$6.66M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.57M

Top Sellers

Rank Fund Capital Flow
1
VOYA Investment Management
VOYA Investment Management
Georgia
-$7.66M
2
Citadel Advisors
Citadel Advisors
Florida
-$5.59M
3
State Street
State Street
Massachusetts
-$5.48M
4
PCM
Portolan Capital Management
Massachusetts
-$3.78M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.53M
Name Holding Trade Value Shares
Change 		Change in
Stake
Axa
26
Axa
France
$3.35M -$79.8K -1,134 -2%
Charles Schwab
27
Charles Schwab
California
$3.23M +$688K +9,778 +23%
BIM
28
BlackRock Investment Management
Delaware
$2.99M +$63.1K +897 +2%
UBS Group
29
UBS Group
Switzerland
$2.69M +$1.32M +18,696 +76%
JP Morgan Chase
30
JP Morgan Chase
New York
$2.6M -$257K -3,653 -8%
CS
31
Credit Suisse
Switzerland
$2.52M +$212K +3,013 +8%
William Blair & Company
32
William Blair & Company
Illinois
$2.43M -$35.8K -509 -1%
QI
33
QS Investors
New York
$2.19M -$225K -3,193 -8%
BA
34
BlackRock Advisors
Delaware
$1.92M +$188K +2,679 +9%
CS
35
Candriam SCA
Luxembourg
$1.82M – – –
New York State Common Retirement Fund
36
New York State Common Retirement Fund
New York
$1.73M +$454K +6,448 +30%
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$1.69M +$121K +1,719 +7%
Brown Advisory
38
Brown Advisory
Maryland
$1.66M – – –
SIP
39
Stoneridge Investment Partners
Pennsylvania
$1.65M +$779K +11,073 +72%
AllianceBernstein
40
AllianceBernstein
Tennessee
$1.33M -$26.8K -381 -2%
American Century Companies
41
American Century Companies
Missouri
$1.15M -$3.73K -53 -0.3%
CT
42
Cambridge Trust
Massachusetts
$1.13M – – –
Swiss National Bank
43
Swiss National Bank
Switzerland
$1.08M – – –
JMPWA
44
JP Morgan Private Wealth Advisors
California
$1.04M – – –
CEP
45
Chicago Equity Partners
Illinois
$979K +$21.2K +302 +2%
OPPM
46
Opus Point Partners Management
New York
$968K +$541K +7,689 +98%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$884K +$85.8K +1,219 +9%
ProShare Advisors
48
ProShare Advisors
Maryland
$867K +$128K +1,817 +15%
California Public Employees Retirement System
49
California Public Employees Retirement System
California
$802K – – –
SIM
50
Spark Investment Management
New York
$785K +$889K +12,634 New
1
2
3 4 5

MACK Hedge Fund Activity: Q4 2015 in Review

139 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q4 2015, worth a combined $636M — down 4% from $663M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new MACK positions and 20 closed out — a net gain of 5 holders — while 48 added to existing stakes and 39 trimmed.

The largest buyer was Putnam Investments, adding an estimated $12.9M. The largest seller was VOYA Investment Management, cutting an estimated $7.66M.

  • 139 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q4 2015, up from 135 in Q3 2015.
  • Funds reported $636M of Merrimack Pharmaceuticals, Inc. stock for Q4 2015, down 4% quarter-over-quarter.
  • 25 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q4 2015 and 20 closed out, a net change of +5 holders.
  • The largest Merrimack Pharmaceuticals, Inc. buyer in Q4 2015 was Putnam Investments, an estimated $12.9M added.
  • The largest Merrimack Pharmaceuticals, Inc. seller in Q4 2015 was VOYA Investment Management, an estimated $7.66M sold.

Based on aggregated 13F filings for Q4 2015.